Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmacology and Therapy
Yuda Anzas Mara
Unknown Affiliation
Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Inhaled corticosteroids and incidence of pneumonia in chronic obstructive pulmonary disease (COPD) patients: A review Yuda Anzas Mara; I Dewa Putu Pramantara S; Zullies Ikawati
Indonesian Journal of Pharmacology and Therapy Vol 5 No 3 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.9775

Abstract

Chronic obstructive pulmonary disease (COPD) is a worldwide respiratory disease that causes significant morbidity and mortality. The primary emphasis in managing COPD is on symptom control and preventing exacerbations. However, there has been ongoing discussion surrounding the safety of inhaled corticosteroids (ICS). This narrative review aimed to examine ICS influence on pneumonia in patients with COPD by consolidating findings from randomized controlled trials and observational studies. The data indicated that the utilization of ICS may be linked to a heightened susceptibility to pneumonia, with varying levels of risk reported across different ICS drugs. Regimens containing fluticasone were found to exhibit an increased susceptibility to pneumonia. The presence of a dose-dependent correlation between ICS and the incidence of pneumonia is apparent. Further investigation is necessary to clarify the fundamental principles and enhance treatment recommendations to maximize the management of COPD while minimizing the incidences of pneumonia associated with ICS.
Asthma in pregnant woman and its management : a review Farni Yuliana Pratiwi; Hadiatussalamah; Intan Adevia Rosnarita; Yuda Anzas Mara; Novia Ariani Dewi
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.3239

Abstract

Asthma is the most common comorbidity in pregnant women and gives 30% of exacerbation experience. The other 30% will see improvement of their symptoms, and the rest will not see the changes. Exacerbations have become a major clinical concern in pregnant women. Medical concerns for the mother and the childbirth included low birth weight, preeclampsia, and preterm delivery. The major goal is to keep asthma under control to ensure mother's health and well-being, as well as fetal growth. Controlling asthma and preventing exacerbations are the main goals of asthma treatment during pregnancy. Treatment for asthma should ideally begin before conception. This is to avoid day-time and night-time symptoms, as well as to keep lung function. Furthermore, fetal oxygenation is a crucial factor during the pregnancy. With a few exceptions, asthma drugs are basically the same in pregnancy as they are in non-pregnant people. Inhaled corticosteroids (ICS) are often used as a controlling treatment. Budesonide is the recommended ICS. Short-acting β-agonist (SABA) preferable as reliever in acute asthma and to relieve exacerbation. As an add-on therapy for medium to high dose ICS, long-acting β-gonists (LABA) is often used. Virus infections and ICS nonadherence are the two most common causes of asthma exacerbations during pregnancy.
Co-Authors Farni Yuliana Pratiwi Hadiatussalamah I Dewa Putu Pramantara S Intan Adevia Rosnarita Novia Ariani Dewi